Adenocarcinoma of the pancreas: recent controversies, current management, and future therapies

GI Cancer

Volumn 1, Issue 3, 1996, Pages 149-161

  Evans, Douglas B ^a,b,c,d   Staley, Charles A ^a,b,c,d   Lee, Jeffrey E ^a,b,c,d   Pisters, Peter W T ^a,b,c,d   Abbruzzese, James L ^a,b,c,d  

^a Departments of Surgical Oncology and Gastrointestinal Medical Oncology and Digestive Diseases ^*  (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001360415     PISSN: 10649700     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (94)

1. Cameron, J. L., Crist D. W., Sitzmann, J. V., et al. (1991) Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am J Surg 161, 120-125.
2. Cameron, J. L., Pitt H. A., Yeo C.i.et al. ( 1993) One hundred and forty-five consecutive pancreaticoduodenectomies without mortality. Ann Surg 217.430-438.
3. Geer, R. J., Brennan, M. F. (1993) Prognostic indicators for survival after resection of pancreatic adenocarcinoma./1m J Surg 165, 68-73.
4. Martin, F. M., Rossi, R. L., Dorrucci, V., e/ ai (1990)Clinical pathologic correlations in patients with periampullary tumors. Arch Surg 125, 723-726.
5. Trede, M., Schwall G., Saeger, H. (1990) Survival after pancreaticoduodenectomy. 118 consecutive resections without an operative mortality. Ann Surg 211, 447-458.
6. Warshaw, A. L., Fernandez-Del Castillo, C. (1992) Pancreatic carcinoma. N Engl J Med 326, 455-465.
7. Evans, D. B., Abbruzzese, J. L., Lee J. E., et al (1995) Preoperative chemoradiation for adenocarcinoma of the pancreas: M.D. Anderson experience. Semin in Surg Oncol, 11, 132-140.
8. Foo, M. L., Gunderson, L. L., Nagorney, D. M., etal ( 1991) Patterns of failure in grossly resected pancreatic ductal adenocarcinoma treated with adjuvant irradiation ±5 fluorouracil. Int J Radiât Oncol BiolPhys 26, 483-489.
9. Gastrointestinal Tumor Study Group. (1987) Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 59, 2006-2010.
10. Yeo, C. J., Hruban, R.H., Kern, S. E., etal. (1994) Adenocarcinoma of the pancreas: factors influencing outcome after pancreaticoduodenectomy-the Johns Hopkins experience. Cancer Bulletin 46, 504-510.
11. Andren-Sandberg, A., Ähren, B., Tranberg, K. G., et al. (1991) Surgical treatment of pancreatic cancer the Swedish experience. Int JPancreatol9, 145-151.
12. Griffin, J. F., Smalley, S. R., Jewell, W. (1990) Patterns of failure after curative resection of pancreatic carcinoma. Cancer 66, 56-61.
13. Ishikawa, O., Ohigashi, H., Sasaki, Y., et al. (1988) Practical usefulness of lymphatic and connective tissue clearance for the carcinoma of the pancreas head. Ann Surg 208, 215-220.
14. Osaki, H., Kinoshita, T., Kosuge, T., et al. (1990) Effectiveness of multimodality treatment for resectable pancreatic cancer. Int J Pancreatoll, 195-200.
15. Tepper, J., Nardi, G., Suit H. (1976) Carcinoma of the pancreas: review of MGH experience from 1963 to 1973. Analysis of surgical failure and implications for radiation therapy. Cancer 37, 1519-1524.
16. Johnstone, P. A., Sindelar, W. F. (1993) Patterns of disease recurrence following definitive therapy of adenocarcinoma of the pancreas using surgery and adjuvant radiotherapy: correlations of clinical trial. Int J Radiât Oncol Biol Phys 27, 831-834.
17. Femandez-del Castillo, C., Warshaw, A. (1993) Peritoneal métastases in pancreatic carcinoma. Hepatogastroenterology 40, 430-432.
18. Alvarez, C., Livingston, E. H., Ashley, S. W., el al. (1993) Cost-benefit analysis of work-up for pancreatic cancer. Am JSurg 165, 53-60.
19. Michelassi. F., Erroi, R, Dawson, P. J. etal. (1989) Experience with 647 consecutive tumors of the duodenum, ampulla, head of the pancreas, and distal common bile duct. Ann Surg 210, 544-556.
20. Tannapfel, A., Wittekind, C., Hunefeld, G. (1992) Ductal adenocarcinoma of the pancreas. Int J Pancreatol 12, 145-152.
21. Rooij, P. D., Rogatko, A., Bennan, M. F. (1991) Evaluation of palliative surgical procedures in unresectable pancreatic cancer. Br J Surg 78, 1053-1058.
22. Lillemoe, K. D., Sauter, P. K., Pitt, H. A., er al. (1993) Current status of surgical palliation of periampullary carcinoma. Surg Gynecol Obstet 176, 1-10.
23. Nitecki, S. S., Sarr, M. G., Colby, T. V., vanHeerden, J. A. (1995) Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg 221, 59-66.
24. Whittington, R., Bryer, M. P., Haller, D. G., et al. (1991) Adjuvant therapy of resected adenocarcinoma of the pancreas. Int J Radiât Oncol Biol Phys 21, 1137-1143.
25. Wtllet, C. G., Lewandroski, K., Warshaw, A. L., et al (1993) Resection margins in carcinoma of the head of the pancreas: implications for radiation therapy. Ann Surg 217, 144-148.
26. The Gastrointestinal Tumor Study Group. (1979) A multi-institutional comparative trial of radiation therapy alone and in combination with 5-fluorouracil for locally unresectable pancreatic carcinoma. Ann Surg 189, 205-208.
27. Ishihawa, O., Ohigashi, H., Sasaki, Y., et al. (1988) Practical usefulness of lymphatic and connective tissue clearance for the carcinoma of the pancreas head. Ann Surg 208, 215-220.
28. Warshaw, A. L., Gu, Z., Wittenberg, J., el al. (1990) Preoperative staging and assessment of resectability of pancreatic cancer. Arch Surg 125, 230-233.
29. Fuhrman, G. M., Chamsangavej, C., Abbruzzese, J. L., et al. (1994) Thin-section contrast-enhanced computed tomography accurately predicts the resectability of malignant pancreatic neoplasms. Am J Surg 167, 104-13.
30. Tyler, D. S., Evans, D. B., (1994) Reoperative pancreaticodudodenectomy. Ann Surg 2, 211-221.
31. Robins, D. B., Katz, R. L., Evans, D. B., et al. (1995) Fine-needle aspiration of the pancreas: in quest of accuracy. Acta Cytologica 39, 1-10.
32. Smith, C. D., Behrns, E., vanHeerden, J. A., Saar, M. G. (1994) Radical pancreaticoduodenectomy for misdiagnosed pancreatic mass. BrJSurg 81, 585-589.
33. vanHeerden, 3. A. (1994) Invited commentary. Arch Surg 129, 642.
34. Warshaw, A. L. (1991) Implications of peritoneal cytology forstaging of early pancreatic cancer. Am J Surg 161, 26-30.
35. Lei, S., Kini, J., Kim, K., Howard, J. M. (1994) Pancreatic cancer. Cytologie study of peritoneal washings. Arch Surg 129, 639-642.
36. Martin, J. K., Goellner, J. R. (1986) Abdominal fluid cytology in patients with gastrointestinal malignant lesions. Mayo Clin Proc 61, 467-t71.
37. Zerbi, A., Balzano, G., Bottura, R., DiCarlo, V. (1994) Reliability of pancreatic cancer staging classifications. Int J Pancreatol 15, 13-18.
38. Leach, S. D., Rose, J. A., Lowy, A. M., et al. (1995) Significance of peritoneal cytology in patients with potentially resectable adenocarcinoma of the pancreatic head. Surgery 118, 472-78.
39. Staley, C. A., Lee, J. E., Cleary, K. A., et al. ( 1995) Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head: patient survival and patterns of treatment failure. In Press: Am J Surg.
40. Moertel, C. G., Childs, D. S. Jr., Reitmeier, R. J., et al. (1969) Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 2, 865-867.
41. Moertel.C. G., Frystak.S.. Hahn, R. G., etal. (1981)Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads and 5-fluorouracil), high dose radiation and 5-fluorouracil. Cancer 48, 1705-1710.
42. Kaiser, M. H., Ellenberg, S. S. (1985) Pancreatic cancer: adjuvant combined radiatioin and chemotherapy following curative resection. Arch Surg 120, 899-903.
43. Ishikawa, O., Ohhigashi, H., Teshima, T., et ai. (1989) Clinical and histopathological appraisal of preoperative irradiation foradenocarcinoma of the pancreaticoduodenal region. J Surg Oncol 40, 143-151.
44. Pilepich, M. V., Miller, H. H. (1980) Preoperative irradiation in carcinoma of the pancreas. Cancer 46, 1945-1949.
45. Kopelson, G. (1983) Curative surgery for adenocarcinoma of the pancreas ampulla of Vater: the role of adjuvant pre- or postoperative radiation therapy. Int J Radial Oncol Biol Phys 9, 911-915.
46. Evans, D. B., Rich, T. A., Byrd, D. R., et al. (1992) Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 127, 1335-1339.
47. Hall, E. J. (1988) Radiobiology forthe radiologist Philadelphia: J.B. LippincottCo 137-63.
48. Femandez-del Castillo, C., Warshaw, A. L. ( 1994) Preoperative evaluation of adenocarcinoma of the pancreas: Massachusetts General Hospital experience. Cancer Bulletin 46, 492-498.
49. Allema, J. H., Reinders, M. E., vanGulik, T. M., et al. (1995) Prognostic factors for survival after pancreaticoduodenectomy for patients with carcinoma of the pancreatic head region. Cancer 75, 2069-2076.
50. Spinier, T. A. W., Obertop, H., Kok, T. C., Jeekel, J. (1989) Adjuvant chemotherapy after resection of adenocarcinoma of the periampullary regional and the head of the pancreas. J Cancer Res Clin Oncol 115, 200-202.
51. Evans, D. B., Abbruzzese, J., Lee, J., Cleary, K., Rich, T. (1994) Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinomaof the pancreas (abstract). Proceedings of the American Society of Clinical Oncology 13, 226.
52. Bakkevold, K. E., Kambestad, B. (1993) Long-term survival following radical and palliative treatment of patients with carcinoma of the pancreas and papilla of Vatter-the prognostic factors influencing the long-term results: a prospective multicentre study. Ear J Surg Oncol 19, 147-161.
53. Cameron, J.L. ( 1995) Pancreaticoduodenectomy: the Johns Hopkins experience. Semin Surg Oncol 11, 114-116.
54. Roder, J.D., Stein, H.J., Hüttl, W., Siewert, J.R. (1992) Pylorus-preserving versus standard pancreaticoduodenectomy: an analysis of 110 pancreatic and periampullary carcinomas. Br J Surg 79, 152-155.
55. Tsao, J.I., Rossi, R.L., Lowell, J.A. (1994) Pylorus-preserving pancreatoduodenectomy. Arch Surg 129, 405-112.
56. Ishikawa, O., Ohigashi, H., Imaoka, S., étal. (1994) Is the long-term survival rate improved by preoperative irradiation prior to Whipple's procedure for adenocarcinoma of the pancreatic head? Arch Surg 129, 1075-1080.
57. Cubilla, A.L., Fortner, J., Fitzgerald, P.J. (1978) Lymph node involvement in carcinoma of the head of the pancreas area. Cancer 41, 880-887.58.
58. Kayahara, M., Nagakawa, T., Kobayashi, H., Mon, K., Nakano, T., Kadoya, N., et al. ( 1992) (Lymphatic flow in carcinoma of the head of the pancreas. Cancer 70, 2061-66.
59. Nagakawa, T., Kobayashi, H., Ueno, K., et al. ( 1994) Clinical study of lymphatic flow to the paraaortic lymph nodes in carcinoma of the head of the pancreas. Cancer 73, 1155-1162.
60. Kayahara, M., Nagakawa, T., Konishi, I., et al. (I991) Clinicopathological study of pancreatic carcinoma with particular reference to the invasion of the extrapancreatic neural plexus. Int J Pancreatol 10, 105-111.
61. Nagakawa, T., Kayahara, M., Ohta, T., e/aJ.(1991)Patternsofneural and plexus invasion of human pancreatic cancer and experimental cancer. Int J Pancreatol 10, 113-119.
62. Nagakawa, T., Mori, K., Nakano, T., et al. (1992) Perineural invasion of carcinoma of the pancreas and biliary tract. Br J Surg 80, 619-621.
63. Fortner, J. (1985) Technique of regional subtotal and total pancreatectomy. Am J Surg 150, 593-600.
64. Ishikawa, O., Ohigashi, H., Imaoka, S., É7a;. (1992) Preoperative indications forextendedpancreatectomy for locally advanced pancreas cancer involving the portal vein. Ann Surg 215, 231-236.
65. Leach, S. D., Lowy, A. M., Fuhrman, G. M., Lee, J. E., Evans, D. B. (1995) Pancreaticoduodenectomy with en-bloc resection of the superior mesenteric-portal vein confluence: surgical outcome using four different techniques. Program of the Pancreas Club, 35.
66. Cusack, J. C, Furhman, G. M., Lee, J. E., Evans, D. B. (1994) Management of unsuspected tumor invastion of the superior mesenteric-portal venous confluence at the time of pancreaticoduodenectomy. Am J Surg 168, 352-354.
67. Evans, D. B., Lee, J. E., Leach, S. D., et al. Vascular resection and intraoperative radiation therapy during pancreaticoduodenectomy: rationale and technique. In Press: Adv Surg.
68. Smith, V. T., Boot, A. J., Smits, A. M., et al. ( 1988) K-ras codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res 16, 7773-7782.
69. Massen, P., Ander-Sandberg, A. ( 1992) Crude isolation of DNA from unselected human pancreatic tissue and amplification by the ploymerase chain reaction of KI-ras oncogene to detect point mutations in pancreatic cancer. Acta Oncol 31, 421-424.
70. Pellegata, N.S., Loseknoot, M., étal. (1992) Detection of K-ras mutations by denaturing gradient gel electrophoresis (DGGE): a study on pancreatic cancer. Anticancer Res 12, 1731-1735.
71. Bos, J.L. (1989) Ras oncogenes in human cancer: a review. Cancer Res 49, 4682-4689.
72. Perucho, M., Capella, G., Shibata, D. (1990) Oncogene activation in human pancreatic adenocarcinoma (Abstract). Proc Am Assoc Cancer Res 31, 478-179.
73. Mukhopadhyay, T., Tainsky, M., Cavebder, A.C., et al. (1991) Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA. Cancer Res 51, 1744-1748.
74. Yamada, H., Sakamato, H., Taira, M., et al. (1986) Amplifications of both c-Ki-ras with a point mutation and c-myc in a primary pancreatic cancer and its metastatic tumors in lymph nodes. Jpn J Cancer Res 77.370-375.
75. Yamada, R.Yoshida, T., Sakamoto, H., e7aJ. (1986) Establishment of a human pancreatic adenocarcinoma cell line (PSW-I) with amplifications of both c-myc and activated c-Ki-ras by a point mutation. Biochem Biophys Res Commun 140, 167-173.
76. Hori, A., Nakaturu, S., Miyoshi, Y., et al. (1992) Frequent somatic mutations of the APC gene in human pancreatic cancer. Cancer Res 52, 6696-6698.
77. Ruggeri, B., Zhang, S. Y., Caamano, J., et al. (1992) Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and Rb-1 tumor-suppressor genes. Oncogene 7, 1503-1511.
78. Ornitz, D. M., Palmiter, R. D., Messing, A., et al. (1985) Elastase I promoter directs expression of growth hormone and SV40 T antigen genes to pancreatic acinar cells in transgenic mice. Cold Spring Harbor Symp Quant Biol 50, 399-409.
79. Quaife, C. J., Pinkert, C. A., Ornitz, D. M., et al. (1987) Pancreatic neoplasia induced by ras expression in acinar cells of transgenic mice. Cell 48, 1023-1034.
80. Sandgren, E. P., Quaife, C. J., Paulovich, A. G., el al. (1991) Pancreatic tumor pathogenesis reflects the causative genetic lesion. Proc NatlAcad Sei USA 88, 93-97.
81. Frazier, M. L., Lilly, B. J., Wu, E. F., et al. (1990) Carbonic anhydrase II gene expression in cell lines from human pancreatic adenocarcinoma. Pancreas 5, 507-514.
82. Pastan, I., Chaudhary, V., Fitzgerald, D. J. (1992) Recombinant toxins as novel therapeutic agents. Ann Rev Biochem 61, 331-354.
83. Von Hoff, D., Marshall, M. H., Heimbrook, D. C., et al. (1992) Activity of a recombinant transforming growth factor-a Pseudomonas exotoxin hybrid protein against primary human tumor colony-forming units. Invest New Drugs 10, 17-22.
84. Kushnaryov, V. M., Redlich, P. N., Sedmak, J., el al. (1992) Cytotoxicity of clostridum difficile toxin A for human colonie and pancreatic carcinoma cell lines. Cancer Res 52, 5096-5099.
85. Phelps, C.J., Lyerly, D.L., JOhnson, J.L., £/aJ. (1991)Construction and expression of the complete difficile toxin A gene in Escherichia coll. Infect Immun 59, 150-153.
86. Abbruzzese, J. L., Levin, B., Ajani, J. A., et al. ( 1989) A phase I trial of recombinant human interferon-g and recombinant human tumor necrosis factor in patients with gastrointestinal cancer. Cancer Res 49, 4057-1061.
87. Abbruzzese, J. L., Levin, B., Ajani, J. A., etal. (1990) A pilot phase II trial of recombinant human interferon-y and recombinant human tumor necrosis factor in patients with advanced gastrointestinal malignancies: results of a trial terminated by excessive toxicity. J Biol Response Modifiers 9, 522-527.
88. Pazdur, R., Ajani, J. A., Abbruzzese, J. L., et al. (1992) Phase U evaluation of fluorouracil and recombinant interferon-a-2 in previously untreated pancreatic adenocarcinoma patients. Cancer 70, 2073-2076.
89. Moore, M., Andersen, J., Bums, H., et al. ( 1995) A randomized trial of gemcitabine versus 5FU as first-line therapy in advanced pancreatic cancer. Proc Am Soc Clini Oncol 14, (Abstract 473).
90. Abbruzzese, J. L., Grunewald, R., Weeks, E. A., et al. ( 1991 ) A phase I clinical, plasma and cellular pharmacology study of Gemcitabine. J Clin Oncol 9, 491-498.
91. Casper, E .S., Green, M. R., Kelsen, D. P., et al. (1995) Phase II trial of gemcitabine (2, 2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 12, 29-34.
92. Abbruzzese, J. L., Gholson, C. F., Daugherty, K., et al. ( 1992) A pilot clinical trial of the cholecystokinin receptor antagonist MK-329 in patients with advanced pancreatic cancer. Pancreas 7, 165-171.
93. Canobbio, L., Boccardo, F., Cannota, D., et al. (1992) Treatment of advanced pancreatic carcinoma with the somatostatin analogue BIM 23014: preliminary results of a pilot study. Cancer 69, 648-650.
94. Evans, D. B., Abbruzzese, J. L., Cleary, K. R., et al. Rapid-fractionation preoperative chemoradiation for malignant periampullary neoplasms. In press: J. R. Coll Surg Edinb.